SEAGEN INC (SGEN)       135.645  -2.35 (-1.71%)

135.645  -2.35 (-1.71%)

US81181C1045 - Common Stock


Fundamental Rating

3

Taking everything into account, SGEN scores 3 out of 10 in our fundamental rating. SGEN was compared to 641 industry peers in the Biotechnology industry. SGEN scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. SGEN is valued quite expensive, but it does show an excellent growth.

Note: SGEN has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

0

SGEN has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for SGEN.

VS Industry

Valuation

Valuation Rating

1

With a price book ratio of 8.92, SGEN is valued correctly.
SGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
When comparing the price book ratio of SGEN to the average industry price book ratio of 1.92, SGEN is valued more expensive than its industry peers. 91% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Book (8.92) VS Industry: 9% outperformed.

444.76
0.07

Growth

Growth Rating

7

Based on estimates for the next 5 years, SGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 33.53% on average per year.
The Revenue has been growing by 30.37% on average over the past 5 years. This is a very strong growth!
SGEN is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 29.01% yearly.

SGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 6.77%.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
SGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -86.49%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -86.49% 2.15% 18.16% 29.71% 33.53%
Revenue30.37% 33.97% 6.77% 23.5% 24.31% 28.25% 29.01%

Health

Health Rating

5

A Current Ratio of 3.80 indicates that SGEN has no problem at all paying its short term obligations.
A Quick Ratio of 3.30 indicates that SGEN has no problem at all paying its short term obligations.
SGEN has an Altman-Z score of 19.12. This indicates that SGEN is financially healthy and little risk of bankruptcy at the moment.
The Altman-Z score of SGEN is much better than the industry average of -0.11. SGEN has a better rating than 92% of its industry peers.

The Debt to Equity ratio of SGEN is in line with the industry averages.
Compared to an average industry Current Ratio of 6.18, SGEN is worse placed to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of SGEN to the average industry Current Ratio of 6.05, SGEN is less able to pay its short term obligations than its industry peers.
The Piotroski-F score of SGEN is 2.00. This is a very weak score and indicates problems in health and profitability for SGEN.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (3.3) VS Industry: 28% outperformed.

0.04
84.53

Current Ratio (3.8) VS Industry: 31% outperformed.

0.08
85.09

Altman-Z (19.12) VS Industry: 92% outperformed.

-2,797.46
658.20

Dividend

Dividend Rating

0

No dividends for SGEN!.

SEAGEN INC135.645

NASDAQ:SGEN (2/6/2023, 12:56:06 PM)-2.35 (-1.71%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 10-27 2022-10-27/amc Earnings (Next) 02-15 2023-02-15/amc
Inst Owners 85.62% Inst Owner Change -1.13%
Ins Owners 0.75% Ins Owner Change 12.77%
Market Cap 25.18B Analysts 78.67
Price Target 166.41 (22.68%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 5.44%
Min EPS beat(2) -5.59% Max EPS beat(2) 16.47%
EPS beat(4) 2 Avg EPS beat(4) 6.39%
Min EPS beat(4) -12.3% Max EPS beat(4) 26.96%
Revenue beat(2) 2 Avg Revenue beat(2) 10.36%
Min Revenue beat(2) 9.27% Max Revenue beat(2) 11.45%
Revenue beat(4) 4 Avg Revenue beat(4) 7.13%
Min Revenue beat(4) 3.53% Max Revenue beat(4) 11.45%
PT rev (1m) -1.04% PT rev (3m) -3.89%
EPS NQ rev (1m) 1.92% EPS NQ rev (3m) 3.45%
EPS NY rev (1m) 0% EPS NY rev (3m) -2.42%
Revenue NQ rev (1m) -0.08% Revenue NQ rev (3m) 0.89%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 0.74%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.51
P/FCF N/A
P/OCF N/A
P/B 8.92
P/tB 10.93
EV/EBITDA N/A
EPS(TTM) -3.45 EY N/A
EPS(NY) -2.23 Fwd EY N/A
FCF(TTM) -3.87 FCFY N/A
OCF(TTM) -3.54 OCFY N/A
SpS 10.04 BVpS 15.2
TBVpS 12.41 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 79.16%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -2.49% GM growth 5Y -2.25%
F-Score 2 Asset Turnover 0.52

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.89%
Profit Quality N/A
Current Ratio 3.8
Quick Ratio 3.3
Altman-Z 19.12
F-Score 2 WACC 9.08%
ROIC/WACC N/A Cap/Depr(3y) 178.13%
Cap/Depr(5y) 146.81% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -86.49% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 36.02%
EPS Next Y 2.15% EPS Next 2Y 18.16%
EPS Next 3Y 29.71% EPS Next 5Y 33.53%
Revenue growth 1Y 6.77% Revenue growth 3Y 33.97%
Revenue growth 5Y 30.37% Revenue growth Q2Q 20.34%
Revenue Next Year 23.5% Revenue Next 2Y 24.31%
Revenue Next 3Y 28.25% Revenue Next 5Y 29.01%
EBIT growth 1Y -82.93% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year 11.73%
EBIT Next 3Y 32.67% EBIT Next 5Y 31.76%
FCF growth 1Y -226.05% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -200.32%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA